Enanta Pharmaceuticals, Inc. (ENTA) NASDAQ

12.03

-0.64(-5.05%)

Updated at June 02 04:00PM

Currency In USD

Enanta Pharmaceuticals, Inc.

Address

500 Arsenal Street

Watertown, MA 02472

United States of America (the)

Phone

617 607 0800

Sector

Healthcare

Industry

Biotechnology

Employees

131

First IPO Date

March 21, 2013

Key Executives

NameTitlePayYear Born
Jay R. LulyPresident, Chief Executive Officer & Director742,2731956
Tara Lynn KiefferChief Product Strategy Officer496,8521978
Matthew KowalskyChief Legal Officer & Corporate Secretary575,6521973
Brendan LuuChief Business Officer622,8561975
Nathaniel S. GardinerConsultant672,6751954
Yat Sun OrChief Scientific Officer814,2851952
Scott T. RottinghausChief Medical Officer863,7061974
Harry R. TroutVP of Finance & Interim Principal Financial Officer01969
Jennifer VieraExecutive Director of Investor Relations & Corporate Communications0N/A
Kathleen S. CappsExecutive Director of Accounting, Controller & Interim Principal Accounting Officer01985

Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.